Aurobindo Pharma Receives Approval For Cefdinir Capsules

Aurobindo Pharma Ltd has announced that the Company has received an approval from the US Food & Drug Administration to market its 300mg Cefdinir Capsules in the US market. The drug falls under the Anti-bacterial segment and is a generic equivalent of Abbott Laboratories, OMNICEF®.Earlier, the Company also received the final approval for 125 mg/5 mL and 250 mg/5 mL oral suspension of this drug from the USFDA.This is Aurobindos 62nd ANDA approval from USFDA.